Literature DB >> 2973061

Peptide-mediated modulation of T-cell allorecognition.

D D Eckels1, J Gorski, J Rothbard, J R Lamb.   

Abstract

Antigen-specific helper T cells recognize a complex of peptide antigen and class II major histocompatibility complex (MHC) gene products. Whether T cells recognize MHC class II alloantigen by a similar mechanism or the native conformation of MHC molecules themselves has yet to be determined. The demonstration that peptide antigens bind directly and specifically to class II molecules has allowed us to examine the influence of foreign peptide binding on T-cell recognition of allogeneic MHC molecules. We report here that an immunodominant, HLA-DR1-restricted peptide of influenza virus hemagglutinin (HA residues 306-320) is able to modulate the recognition of alloantigen by human DR1-specific T-cell clones. For some T-cell clones, but not all, the HA peptide inhibited allorecognition in a dose-dependent manner. However, in one instance, the proliferative response to alloantigen was enhanced in the presence of HA peptide. These results suggest that the specificities of T-cell responses to allogeneic MHC molecules are heterogeneous, which may be influenced by different peptides occupying the class II MHC combining site and by the diversity of antigen-specific receptors of T lymphocytes recognizing the same MHC/peptide complex.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973061      PMCID: PMC282393          DOI: 10.1073/pnas.85.21.8191

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex.

Authors:  R H Schwartz
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

2.  Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha 2 domain of HLA-A2.

Authors:  P Parham; C Clayberger; S L Zorn; D S Ludwig; G K Schoolnik; A M Krensky
Journal:  Nature       Date:  1987 Feb 12-18       Impact factor: 49.962

3.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

Review 4.  Functional sites of human class I MHC molecules: paradigms a dozen?

Authors:  P Parham
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

5.  MHC protein structure. Those images that yet fresh images beget.

Authors:  A Townsend; A McMichael
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

6.  H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA peptide.

Authors:  J L Maryanski; P Pala; G Corradin; B R Jordan; J C Cerottini
Journal:  Nature       Date:  1986 Dec 11-17       Impact factor: 49.962

7.  Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes.

Authors:  P A Robbins; E L Evans; A H Ding; N L Warner; F M Brodsky
Journal:  Hum Immunol       Date:  1987-04       Impact factor: 2.850

8.  Isolation and characterization of antigen-Ia complexes involved in T cell recognition.

Authors:  S Buus; A Sette; S M Colon; D M Jenis; H M Grey
Journal:  Cell       Date:  1986-12-26       Impact factor: 41.582

9.  Structure of the human class I histocompatibility antigen, HLA-A2.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

10.  Selective modification of a private I-A allo-stimulating determinant(s) upon association of antigen with an antigen-presenting cell.

Authors:  K L Rock; B Benacerraf
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more
  13 in total

1.  Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.

Authors:  B Murphy; C C Magee; S I Alexander; A M Waaga; H W Snoeck; J P Vella; C B Carpenter; M H Sayegh
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

2.  Self peptide requirement for class II major histocompatibility complex allorecognition.

Authors:  S Demotz; A Sette; K Sakaguchi; R Buchner; E Appella; H M Grey
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

Review 3.  The structural basis of alloreactivity.

Authors:  R Lechler; G Lombardi
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

Review 4.  Mechanism of cellular rejection in transplantation.

Authors:  Elizabeth Ingulli
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

5.  Stress-induced modulation of antigen-presenting cell function.

Authors:  A D Rees; Y Donati; G Lombardi; J Lamb; B Polla; R Lechler
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

6.  Delineation of antigen contact residues on an MHC class II molecule.

Authors:  J Peccoud; P Dellabona; P Allen; C Benoist; D Mathis
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

7.  T cell receptor V beta gene usage in a human alloreactive response. Shared structural features among HLA-B27-specific T cell clones.

Authors:  R Bragado; P Lauzurica; D López; J A López de Castro
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

8.  MHC class II-derived peptides can bind to class II molecules, including self molecules, and prevent antigen presentation.

Authors:  E F Rosloniec; L J Vitez; S Buus; J H Freed
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

9.  Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.

Authors:  J Fangmann; R Dalchau; J W Fabre
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Corecognition of HLA-A1 and HLA-DPw3 by a human CD4+ alloreactive T lymphocyte clone.

Authors:  S Essaket; J Fabron; C de Preval; M Thomsen
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.